AVEO Pharmaceuticals, Inc. AVEO
Set alert
At close · Jan 19
52-week range unavailable
- Open
- 15.00
- Prev close
- 15.00
- Mkt cap
- 521.45M
- Vol
- 245.30K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.99
- High
- 15.00
- Forward P/E
- 42.86
- Beta
- 0.98
- Short ratio
- 2.00
- Inst. own
- 34.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 13, 2023
- 50-d avg
- 14.90
- 200-d avg
- 9.19
- 1y target
- 15.00
2Y chart
Events in this range
- Nov 8, 2021Earnings: —; estimate -0.36; surprise —%
- Mar 14, 2022Earnings: —; estimate -0.35; surprise —%
- May 5, 2022Earnings: —; estimate -0.26; surprise —%
- Aug 4, 2022Earnings: —; estimate -0.27; surprise —%
- Oct 18, 2022Downgrade: HC Wainwright & Co. · Buy → Neutral
- Oct 19, 2022Downgrade: Baird · Outperform → Neutral
- Oct 24, 2022Downgrade: SVB Leerink · Outperform → Market Perform
- Oct 31, 2022Downgrade: JonesTrading · Buy → Hold
- Nov 7, 2022Earnings: —; estimate -0.16; surprise —%
- Nov 8, 2022Downgrade: Stifel · Buy → Hold
Signals (32)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Jan 12, 2023 | 3 years ago |
| MACD: Sell Signal | Nov 4, 2022 | 3 years ago |
| RSI: Overbought | Oct 14, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 3, 2022 | 4 years ago |
| SMA: Bullish | Sep 28, 2022 | 4 years ago |
| SMA: Bearish | Sep 27, 2022 | 4 years ago |
| SMA: Bullish | Sep 26, 2022 | 4 years ago |
| SMA: Bearish | Sep 23, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 26, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 23, 2022 | 4 years ago |
| RSI: Overbought | Aug 23, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 16, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 5, 2022 | 4 years ago |
| RSI: Overbought | Aug 4, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 15, 2022 | 4 years ago |
| RSI: Overbought | Jun 30, 2022 | 4 years ago |
| RSI: Overbought | Jun 23, 2022 | 4 years ago |
| SMA: Bullish | Jun 21, 2022 | 4 years ago |
| MACD: Buy Signal | May 23, 2022 | 4 years ago |
| RSI: Oversold | May 9, 2022 | 4 years ago |
| SMA: Bearish | May 4, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 1, 2022 | 4 years ago |
| RSI: Overbought | Mar 29, 2022 | 4 years ago |
| RSI: Overbought | Mar 15, 2022 | 4 years ago |
| SMA: Bullish | Mar 9, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 31, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 7, 2022 | 4 years ago |
| RSI: Oversold | Jan 7, 2022 | 4 years ago |
| RSI: Oversold | Dec 29, 2021 | 4 years ago |
| MACD: Buy Signal | Dec 21, 2021 | 4 years ago |
| RSI: Oversold | Dec 14, 2021 | 4 years ago |
| RSI: Oversold | Dec 2, 2021 | 4 years ago |
Key statistics
- Market cap
- 521.45M
- Enterprise value
- 482.73M
- Trailing P/E
- 0.00
- Forward P/E
- 42.86
- PEG ratio
- 0.00
- Price / sales
- 5.53
- Price / book
- 18.01
- EPS (TTM)
- -1.20
- Beta
- 0.98
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -30.79%
- Revenue (TTM)
- 94.32M
- Revenue growth
- 100.70%
- Free cash flow
- -13.00M
- Total cash
- 77.40M
- Total debt
- 38.68M
- Return on equity
- -72.53%
- Shares outstanding
- 34.76M
- Short % of float
- 2.36%
- 50-day average
- 14.90
- 200-day average
- 9.19
Analyst view
Consensus: hold
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 13, 2023
Expected Mar 13, 2023. Consensus EPS estimate -0.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 13, 2023 | Dec 1, 2022 | -0.04 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | -0.16 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.27 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.26 | — | — | — |
| Mar 14, 2022 | Dec 1, 2021 | -0.35 | — | — | — |
| Nov 8, 2021 | Sep 1, 2021 | -0.36 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2022 | Stifel | down | Buy | Hold |
| Oct 31, 2022 | JonesTrading | down | Buy | Hold |
| Oct 24, 2022 | SVB Leerink | down | Outperform | Market Perform |
| Oct 19, 2022 | Baird | down | Outperform | Neutral |
| Oct 18, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Jul 12, 2021 | HC Wainwright & Co. | main | — | Buy |
About AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent's Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aveooncology.com
News
- Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
- Natera, Aveta partner on late-stage head and neck cancer trial
- CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
- AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
- AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
- AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- 4 Drug Stocks That More Than Doubled This Year
- Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
- AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions
- What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?
Your note
Sign in to keep a note on AVEO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY MICHAEL P | Chief Executive Officer | Conversion of Exercise of derivative security | Dec 19, 2022 | 340,167 |
| BARRETT PETER | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 7, 2019 | 0 |
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 18, 2020 | 0 |
| FERRARESSO MICHAEL | Officer | Purchase | Aug 9, 2021 | 9,235 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 18, 2020 | 0 |
| GROWTH EQUITY OPPORTUNITIES FUND IV, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 18, 2020 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 11.37% | 3,952,957 | 59.29M | Sep 29, 2022 |
| AIGH Capital Management LLC | 7.88% | 2,739,255 | 41.09M | Sep 29, 2022 |
| Rubric Capital Management LP | 4.79% | 1,664,667 | 24.97M | Sep 29, 2022 |
| Vanguard Group, Inc. (The) | 4.34% | 1,507,955 | 22.62M | Sep 29, 2022 |
| Worth Venture Partners, Llc | 1.97% | 685,026 | 10.28M | Sep 29, 2022 |
| J. Goldman & Co., L.P. | 1.89% | 656,161 | 9.84M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 1,039,472 | 15.59M | Sep 29, 2022 |
| IndexIQ Tr-IQ Merger Arbitrage ETF | 1.46% | 508,822 | 7.63M | Dec 30, 2022 |
| Arbitrage Fund | 1.31% | 456,464 | 6.85M | Nov 29, 2022 |
| Vanguard Extended Market Index Fund | 1.19% | 412,120 | 6.18M | Sep 29, 2022 |
| Fidelity Extended Market Index Fund | 0.39% | 136,353 | 2.05M | Nov 29, 2022 |
| AltShares Merger Arbitrage ETF | 0.39% | 135,109 | 2.03M | Nov 29, 2022 |